Humira sBLA Submitted For Ankylosing Spondylitis
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott filed a supplemental BLA with FDA seeking approval of the TNF-inhibitor Humira (adalimumab) as a treatment for ankylosing spondylitis Oct. 4
You may also be interested in...
Humira To Compete With Remicade, Enbrel in Ankylosing Spondylitis
FDA approved Abbott’s adalimumab for reducing signs and symptoms in patients with active ankylosing spondylitis.
Humira To Compete With Remicade, Enbrel in Ankylosing Spondylitis
FDA approved Abbott’s adalimumab for reducing signs and symptoms in patients with active ankylosing spondylitis.
Abbott Anticipates Humira sBLA For Crohn’s Disease By Year-End
Application would be buoyed by new Phase III remission data.